The impact of androgen deprivation therapy or androgen blockage therapy on the upregulation receptor activity of Gallium68 Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) scans in men with castrate resistant prostate cancer and the use of PSMA targeted therapies.

Trial Profile

The impact of androgen deprivation therapy or androgen blockage therapy on the upregulation receptor activity of Gallium68 Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) scans in men with castrate resistant prostate cancer and the use of PSMA targeted therapies.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Gallium 68 PSMA (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Diagnostic use
  • Acronyms ADT and Me Study
  • Most Recent Events

    • 03 Aug 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top